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Background: The problem of prosthetic heart valve selection in fertile women with acquired heart defects remains
crucial in modern cardiology. Mechanical heart valves require lifelong indirect anticoagulant therapy, which has
significant fetal toxicity and is unacceptable for women planning pregnancy. Bioprosthetic heart valves are the best
choice for fertile women; however, their durability is limited, and reoperations are required.
Case presentation: We describe the clinical case of a 21-year-old Russian woman with infectious endocarditis who
underwent heart valve replacement with an epoxy-treated mitral valve prosthesis.
Conclusions: Epoxy-treated bioprosthetic heart valves can be used without long-term anticoagulant therapy
because of their optimal hemodynamic functional parameters. Moreover, their high thromboresistance and
resistance to infection improve patients’ quality of life in their late postoperative period. We recommend these
valves both in older persons and in young patients including women who are planning pregnancy.
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Acquired heart disease (AHD) is currently the most com-
mon cardiac disease among young adults in Russia, with
infectious and rheumatic valvular lesions predominating
[1]. In contrast, European hospitals report a higher preva-
lence of degenerative valve disease, and thus their heart
valve replacement patients tend to be older persons [2].
Heart valve replacement surgery significantly prolongs
life expectancy and improves quality of life in patients
with AHD. There are two basic types of prosthetic heart
valves used in current clinical practice: mechanical and
bioprosthetic. Deciding which valve to use requires care-
ful consideration of the specific advantages and disad-
vantages of the valve types and integration of this
knowledge into the clinical characteristics and personal
preferences of the individual patient [3].
European clinics have solved the problem of selecting
prosthetic heart valves for patients with AHD by imple-
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[3]. Unfortunately, European and American guidelines
are not always suitable for clinical practice in Russia,
because of AHD etiology as well as the age of patients
undergoing heart valve replacement.
Young women planning pregnancy are considered high
risk patients who require careful selection of the optimal
prosthetic heart valve. Mechanical heart valve prostheses,
which require lifelong indirect anticoagulant therapy (war-
farin, phenindione), are not appropriate because of the
teratogenic potential of indirect anticoagulants [3, 4].
Current AHA and ESC guidelines should be followed for
selecting the type of prosthesis. According to them, the
preferable valve choice for this patient group is bioprosth-
esis [2, 3]. However, bioprosthetic heart valve replacement
in young patients requires future reoperations due to the
development of bioprosthesis dysfunction. Therefore, al-
ternative options for preservation of xenogenic material
are required.
The main issue with bioprosthetic heart valves is their
finite lifespan and high risk of reoperation in the future
[2]. The average lifespan of mechanical valves is 20 to 30icle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Barbarash et al. Journal of Medical Case Reports  (2016) 10:51 Page 2 of 5years, making these valves more suitable for younger pa-
tients. In contrast, bioprosthetic heart valves have 8 to
15 years’ durability, depending on patient age, prosthesis
type and position [2, 5, 6]. The first successful pregnancy
and delivery in a patient with a prosthetic mitral valve
(Starr–Edwards) was reported in 1966 [7]. Warfarin
embryopathy was first described by Hall in 1965 [7, 8].
A study of pregnant women with prosthetic heart
valves in Denmark with a 30-year follow-up confirmed
fetal and maternal complications associated with anti-
coagulant therapy [9]. The true incidence of warfarin-
induced embryopathy is difficult to establish. Studies
have reported incidences ranging from less than 5 % to
more than 67 %; other researchers have estimated that it
occurs in 4 to 10 % of cases [10].
Several studies have demonstrated the safety of unfrac-
tionated heparin therapy (UFH). Heparin is thought to
be an ideal drug in pregnancy, because it does not cross
the placenta, and therefore has no effect on the fetus.
However, the reliability and efficacy of UFH has not
been proven [11–13].
Bioprosthetic heart valves are preferred over mechan-
ical valves in women of childbearing age who are plan-
ning pregnancy [2]. Their main advantage is that they
allow a better quality of life, mainly because patients do
not require anticoagulation therapy (while normal sinus
rhythm is maintained in patients in the postoperative
period) and the valves have greater resistance to infec-
tion. However, bioprosthetic heart valves have less dur-
ability than mechanical valves [14]. The risk of structural
valve deterioration depends on patient age, with signifi-
cantly higher risk in young patients. This particular issue
determines the selection of the optimal prosthetic heart
valve. Thus, approximately 40 % of heart valve implanta-
tions in the USA and Europe are bioprosthetic, resulting
in higher life expectancy [2]. Bioprosthetic valves are
mainly used in older patients with underlying degenera-
tive processes or coronary artery disease. In comparison,
only 7 to 10 % of heart valves implanted in younger pa-
tients with rheumatic heart diseases in Russia and other
developing countries are bioprosthetic, and they carry a
relatively high risk of graft dysfunction.
Thus, the main advantage of bioprosthetic heart
valves is that most patients avoid anticoagulation ther-
apy. Their significant disadvantage is a high risk of
structural valve deterioration in the late postoperative
period. Specific complications that limit bioprosthetic
durability and result in reoperations in the second
decade after implantation include primary tissue de-
generation associated with most xenografts, calcifica-
tion and prosthetic valve endocarditis. If prosthetic
valve endocarditis develops as a consequence of non-
compliance with preventive therapy, primary tissue
degeneration occurs as a separate issue, associatedwith poorly investigated biological tissue transforma-
tions during prosthesis production and the natural-
biological function in the recipient. Despite the fact
that the problem of bioprosthesis calcification has
existed since the earliest models, the pathogenetic
mechanisms of xenograft calcification have not been
fully investigated. Extensive clinical experience in the
application of bioprosthetic heart valves has accumu-
lated worldwide, including different valve models fab-
ricated from different biological tissues and various
methods of valve preservation and anti-calcification
treatment. Hundreds of thousands of bioprostheses
have been implanted and management strategies for
patients in the early and late postoperative periods
have been developed, but the problem of bioprosthetic
heart valve dysfunction remains far from resolved.
There is no consensus on bioprostheses in the litera-
ture [15]. Sudden mechanical valve failure is usually a
fatal event; bioprosthetic failure progresses for years
and allows elective reoperation [3].
Several Russian clinics now use new-generation
diepoxy-treated bioprostheses. The Russian experience
in this area appears to be rare, as no other country has
treated xenografts with epoxy compounds; most con-
tinue to use glutaraldehyde-treated biomaterials. The hy-
pothesis that the biochemical transformations occurring
in xenograft implanted prosthetic devices can be affected
by conserving agents has resulted in a new conservation
method that increases resistance to biodegradation and
calcification. Our experience suggests that ethylene gly-
col diglycidyl ether, a new-generation conserving agent,
improves the structural stability and calcification-
resistant properties of bioprosthetic heart valves [15].
We have an 18-year single-center experience with mi-
tral valve replacement using xenoaortic (epoxy-treated)
bioprostheses. “KemKor” bioprostheses were implanted
in the period from 1991 to 2001 and “PeriCor” pros-
theses from 2001 to 2009. A total of 382 xenoaortic bio-
prosthetic heart valves were implanted in the mitral
position (the mean age of patients at the time of surgery
was 48.8±10.2). The surgeries were performed according
to the standard procedure for mitral valve replacement
under normothermic cardiopulmonary bypass. The in-
hospital mortality was 5.8 % (n=22), and 360 patients
were successfully discharged from hospital. By the end
of 2014, the completeness of patients’ follow-up was
94.5 % with a mean follow-up period of 8.0±4.4 years
and a follow-up scope of 2792 patient-years. The long-
term mortality, including the redo procedures, was 29.2 %
(n=105) of the total number of discharged patients. Of the
total number of discharged patients, 130 patients (36.1 %)
underwent redo procedures because of the development
of degenerative changes. Bioprosthetic dysfunction was
confirmed by morphological studies in 126 cases (96.9 %).
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with calcification of the xenogenic material, 15.1 % (n=19)
reported bioprosthetic dysfunction with no signs of calcifi-
cation, and 27 % (n=34) had prosthetic endocarditis. One
patient (0.8 %) had prosthetic valve thrombosis, associated
with infected tissue prosthesis; nine (7.1 %) patients re-
ported a combination of signs of calcification and
infection.
A database was established to allow a detailed analysis
of outcomes after KemKor and PeriCor bioprosthetic
valve replacements. Below we present the clinical case of
a young woman with AHD who received a bioprosthetic
heart valve designed in our clinic.
Case presentation
A 21-year-old Russian woman at 38 weeks’ gestation was
admitted to the Regional Maternity Hospital, Kemerovo,
Russia in March 1998. She presented in critical condi-
tion associated with decompensated heart failure. The
first manifestations of the disease had occurred at 28
weeks’ gestation after an acute viral respiratory infection
with long-lasting elevated body temperature. Toxic
shock syndrome developed, and her heart failure symp-
toms worsened. Echocardiography (ECHO) revealed in-
fective endocarditis, mitral valve failure (rupture of the
anterior mitral valve leaflet with grade IV regurgitation)
and mobile vegetation at the posterior leaflet. A healthy
baby was delivered by cesarean section at 39 weeks’ ges-
tation. She then received goal-directed therapy in the
cardiac surgery unit aimed at suppressing sepsis and
compensating for heart failure: initially New York Heart
Association (NYHA) class IV. Mitral valve replacement
with bioprosthetic heart valve KemKor-30 was per-
formed 6 weeks after delivery. The management of pri-
mary infective endocarditis (enterococcal infection
verified by blood culture study) and subsequent preven-
tion of prosthetic endocarditis was performed in accord-
ance with the existing (at the time of the follow-up
period) guidelines. She received ceftriaxone, 2 g/day ad-
ministered intravenously in a single daily dose. Her post-
operative period was without complications (discharge
with NYHA class II). The choice of a bioprosthetic heart
valve was determined by her desire for future pregnancy.
Indirect anticoagulant (phenindione) therapy was
discontinued 6 months after surgery, because of the ab-
sence of heart failure symptoms and cardiac arrhythmias
and satisfactory prosthesis function. She became preg-
nant again in 2002, 3 years after surgery. In the follow-
up period, she did not receive any cardiotropic agents
and anticoagulants, her condition was satisfactory. Her
pregnancy was not contraindicated, according to clinical
assessment and testing. She was supervised by surgeons,
cardiologists and obstetricians during her pregnancy.
She delivered a healthy baby boy vaginally withoutcomplications. Her child was breastfed. Annual exami-
nations were performed to monitor for bioprosthetic
valve failure, because breastfeeding is known to increase
the risk of calcification.
A moderate calcific degeneration of the leaflet was
found 12 years after heart valve replacement, a common
finding in bioprosthetic heart valves. Dynamic ECHO re-
vealed a moderate decrease in the effective orifice area
and an increase in the mean diastolic transprosthetic
pressure gradient and mean transprosthetic blood flow
velocity. However, these changes still met the criteria for
normal prosthetic heart valve function (Fig. 1). She did
not receive medical treatment.
She reported pregnancy at 5 weeks’ gestation. Despite
the risk of complications associated with limited durabil-
ity of the prosthetic heart valve and hormonal changes
associated with pregnancy and lactation, which could
worsen structural valve deterioration, she decided to
continue her pregnancy. There were no signs of cardiac
arrhythmias on her daily electrocardiograms (ECGs) or
signs of heart failure during patient monitoring.
Five ECHO examinations revealed the natural physio-
logical changes caused by cardiovascular adaptation to
the increased metabolic needs of pregnancy to ensure
adequate oxygenated blood delivery to the peripheral
tissues and the fetus. The changes included increased
circulating blood volume, heart rate, myocardial con-
tractility and systemic blood pressure, which certainly
influenced intracardiac hemodynamic parameters [10].
Her left atrium enlarged from 3.4 to 4.0 cm and her left
ventricular end-diastolic volume rose from 81 to 99 ml,
related to the circulating blood volume and increased
preload during pregnancy. A similar mechanism was
identified in the central regurgitation across the bio-
prosthesis registered at 8 weeks’ gestation. The initial
transprosthetic regurgitation of > grade I had increased
to grade I to II by delivery. However, the absence of sig-
nificant changes in her diastolic gradient and blood flow
velocity confirmed that the prosthesis maintained func-
tional durability (Fig. 2).
Her elevated cardiac output and her left ventricular dila-
tation were caused by increased myocardial contractility.
Her left ventricular ejection fraction rose from 63 to 76 %
during her pregnancy. The physiological increase in her
heart rate in the last trimester was associated with the
overestimation of the effective orifice area. Tachycardia
affected the Doppler characteristics of the mitral valve and
biased the resulting ECHO parameters. Her mean pul-
monary artery pressure increased from 10 mmHg at 5
weeks’ gestation to 16 mmHg at 39 weeks’ gestation, con-
tributing to a moderate increase in peripheral resistance
and arterial blood pressure after 32 weeks’ gestation.
The bioprosthesis, implanted in the mitral position,
contributed to the physiological changes in functional
Fig. 1 Hemodynamic parameters with the bioprosthesis during follow-up. Mean DPG – mean diastolic pressure gradient, mmHG; Mean BFV –
mean blood flow velocity; EOA – effective orifice area
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whereas cardiac reserve was not impaired during her
pregnancy.
Natural vaginal delivery of a healthy full-term male
newborn (3670 kg, 52 cm, Apgar scores 8 to 9) occurred
in October 2011, at 39 weeks’ gestation. Her postpartum
period was uneventful and she was discharged on the
sixth day after delivery.
ECHO findings included reduction of bioprosthesis
regurgitation to grade I, reduction of left ventricular end-Fig. 2 Bioprosthesis hemodynamic parameters during pregnancy. Mean DP
blood flow velocity; EOA – effective orifice areadiastolic volume to 85 mL and increase in mean pulmonary
artery pressure to 12 mmHg, indicating stabilization of her
intracardiac hemodynamics (Fig. 2).
No significant health problems arose for our patient or
her baby during a 2-year follow-up. Her baby was breast-
fed for 12 months. Our patient did not have any signs of
heart failure or clinically significant cardiac arrhythmias.
There were no indications for cardiotropic drugs. Dy-
namic ECHO assessment of the mitral bioprosthesis
revealed its functional safety, despite the thickening ofG – mean diastolic pressure gradient, mmHG; Mean BFV – mean
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satisfactory left ventricular ejection fraction (64 %),
target blood pressure, mean diastolic transprosthetic
gradient (4.2 mmHg) and mean transprosthetic flow vel-
ocity (96 cm/second) were maintained. The effective ori-
fice area was 2.8 cm2. Her left ventricular end-diastolic
volume (84 mL) and mean pulmonary artery pressure
(13 mmHg) remained stable. Despite grade I regurgita-
tion, the size of her left atrium did not exceed the upper
limit of normal (3.9 cm).
Conclusions
This clinical case demonstrates the use of bioprosthetic
heart valves without the need for long-term indirect anti-
coagulant therapy. Bioprosthetic heart valves are an alter-
native to mechanical valve prostheses for women of
childbearing age. The experience of this young woman
with two pregnancies and lactation periods revealed no
signs of bioprosthetic valve dysfunction with the diepoxy-
treated bioprosthetic valve and supports the use of bio-
prosthetic heart valves in patients who are planning
pregnancies.
Our extensive experience with epoxy-treated biopros-
thetic heart valves such as KemKor and PeriCor indicates
that patients can avoid long-term anticoagulant therapy be-
cause of their optimal hemodynamic functional parameters,
thromboresistance and high resistance to infection, without
worsening quality of life in the late postoperative period.
We recommend these valves both in older persons and in
young patients with an active lifestyle, including women
who are planning pregnancy.
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